SCHEMBL3799157

SCHEMBL3799157

Cc1csc2ncnc(Nc3ccccc3C(C)C)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 2/20 0.50
HTT P42858 3/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
DYRK3 O43781 3/20 0.45
MAP4K4 O95819 3/20 0.45
EGFR P00533 3/20 0.45
PIM1 P11309 3/20 0.45
CLK2 P49760 3/20 0.45
IRAK1 P51617 3/20 0.45
CSNK2A1 P68400 3/20 0.45
MAP4K2 Q12851 3/20 0.45
DYRK1A Q13627 3/20 0.45
AURKB Q96GD4 3/20 0.45
CLK4 Q9HAZ1 3/20 0.45
PIM3 Q86V86 2/20 0.45
MKNK2 Q9HBH9 2/20 0.45
HIPK4 Q8NE63 2/20 0.45
SRPK1 Q96SB4 1/20 0.45
CSNK1G1 Q9HCP0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3801142 0.88 RAB9A (0.47) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3805706 0.85 PIP4K2C (0.50) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3799470 0.82 PIP4K2C (0.52) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3799687 0.82 PIP4K2C (0.52) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3799987 0.81 PIP4K2C (0.47) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3797468 0.81 RAB9A (0.47) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3801425 0.81 PIP4K2C (0.51) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3797440 0.80 HTT (0.54) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3802591 0.80 PIP4K2C (0.46) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3
SCHEMBL3796872 0.80 RAB9A (0.47) PIP4K2CHTTRAB9ASMN1; SMN2DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP claimed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO claimed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO claimed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO disclosed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK PIP4K2C 138/4885HTT 3454/4885RAB9A 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.